2797 |
Quality of Life After TAVI: What Do We Know? Why Should You Care? |
David Joel Cohen |
May. 09. 14 |
2796 |
REPRISE II: A Prospective Registry Study of Transcatheter Aortic Valve Replacement with a Repositionable Transcatheter Heart Valve in Patients with Severe Aortic Stenosis |
Ian T. Meredith |
May. 09. 14 |
2795 |
Registry Results of Self-expandable CoreValve Studies |
Eberhard Grube |
May. 09. 14 |
2794 |
Updates from the Balloon-expandable Sapien PARTNER Trials |
Phillippe Genereux |
May. 09. 14 |
2793 |
MSCT Is Mandatory Before and Useful After TAVI |
Bernard R. Chevalier |
May. 09. 14 |
2792 |
Echocardiographic Evaluation of AV Hemodynamics and Morphology |
Jong-Min Song |
May. 09. 14 |
2791 |
Beyond D2B Time: What Is The Next Solutions? |
Naoto Inoue |
May. 09. 14 |
2790 |
Speed to Treatment: Faster D2B Time, but Not Fewer Death |
Mun Kyung Hong |
May. 09. 14 |
2789 |
TASTE Trial: No Benefits, Time to Rethink? |
Bernard R. Chevalier |
May. 09. 14 |
2788 |
Guideline Today: Some Benefits, Optional Choice |
Cindy L. Grines |
May. 09. 14 |